A carefully designed approach to very-early-phase development that includes rapid generation of accurate, high-quality data supporting relevant candidate evaluation allows the efficient elimination of candidates not likely to succeed. By failing fast, or more specifically sufficiently early, the cost, resources, and effort involved in advancing these molecules to later stages can be redirected to candidates with a much higher likelihood of success. Working with a contract development and manufacturing organization (CDMO) like Mikart with extensive formulation, method, and process development expertise and dedicated very-small-scale lab equipment, drug developers can make go/no-go decisions with confidence even before they reach the preclinical development stage, saving time, money, and resources. Download this article to learn more about how partnering with a CDMO like Mikart can lead to drug development success.